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Abstract
Background: Ovarian cancer early detection markers CA125, CA15.3, HE4, and CA72.4 vary between healthy women,
limiting their utility for screening.
Methods: We evaluated cross-sectional relationships between lifestyle and reproductive factors and these markers
among controls (n = 1910) from a nested case-control study in the European Prospective Investigation into
Cancer and Nutrition (EPIC). Improvements in discrimination of prediction models adjusting for correlates of the markers
were evaluated among postmenopausal women in the nested case-control study (n = 590 cases). Generalized linear
models were used to calculate geometric means of CA125, CA15.3, and HE4. CA72.4 above vs. below limit of detection
was evaluated using logistic regression. Early detection prediction was modeled using conditional logistic regression.
Results: CA125 concentrations were lower, and CA15.3 higher, in post- vs. premenopausal women (p≤ 0.02). Among
postmenopausal women, CA125 was higher among women with higher parity and older age at menopause (ptrend≤ 0.
02), but lower among women reporting oophorectomy, hysterectomy, ever use of estrogen-only hormone therapy, or
current smoking (p < 0.01). CA15.3 concentrations were higher among heavier women and in former smokers (p≤ 0.03).
HE4 was higher with older age at blood collection and in current smokers, and inversely associated with OC use
duration, parity, and older age at menopause (≤ 0.02). No associations were observed with CA72.4. Adjusting for
correlates of the markers in prediction models did not improve the discrimination.
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Conclusions: This study provides insights into sources of variation in ovarian cancer early detection markers in healthy
women and informs about the utility of individualizing marker cutpoints based on epidemiologic factors.
Keywords: Ovarian cancer, Early detection markers, CA125, CA15.3, HE4
Background
Mucins CA125 (MUC16) and CA15.3 (MUC1) are
membrane-bound, high molecular weight glycoproteins
expressed in certain epithelial tissues, as well as some
epithelial cancers [1, 2]. CA125 is expressed in >80% of
ovarian cancers, while CA15.3 is commonly expressed in
breast cancer [2]. Human epididymis protein 4 (HE4) is
a member of the whey acidic protein family and is
widely expressed in ovarian cancers [3]. CA72.4, is a
mucin-like glycoprotein expressed in gastric, breast, and
ovarian cancers [4]. Circulating concentrations of
CA125, CA15.3, HE4 and CA72.4 have been investigated
for ovarian cancer early detection. However, these
markers have limited predictive utility for ovarian cancer
screening given low sensitivity and specificity for early
stage disease, as described in an earlier investigation by
our group [5]. Variable circulating concentrations of
these markers are found in healthy women, limiting their
utility for screening.
Reproductive and lifestyle factors previously shown to
impact CA125, CA15.3 and HE4 concentrations in
healthy women include age, hysterectomy, oral contra-
ceptive (OC) use, body mass index (BMI; kg/m2), and
smoking status [6–13]. CA125 concentrations are higher
in premenopausal, relative to postmenopausal, women
[8, 13–17], and different screening cutpoints have been
proposed based on menopausal status (e.g., 98th percent-
ile in healthy women, premenopausal: 52 U/mL; post-
menopausal: 35 u/mL [8]).
Given these observations in healthy women, under-
standing correlates of early detection markers could help
improve the utility of these markers in early detection
prediction models. We therefore (i) describe associations
between lifestyle and reproductive factors and CA125,
CA15.3, HE4, and CA72.4; and, (ii) evaluate whether
adjusting for these factors in early detection prediction
models including early detection marker data improves
the discriminatory capacity of these markers in a large,
prospective investigation in the European Prospective
Investigation into Cancer and Nutrition (EPIC) cohort.
Methods
The EPIC cohort was established between 1992 and
2000 in 23 centers in 10 European countries: Denmark,
France, Germany, Greece, Italy, the Netherlands,
Norway, Spain, Sweden, and the United Kingdom. Ap-
proximately 500,000 participants were recruited at study
baseline. Study participants completed questionnaires
describing diet, reproductive history, menstrual factors,
exogenous hormone use, as well as disease history,
smoking, and alcohol use. A total of 385,747 (74%) par-
ticipants provided a blood sample at or near baseline.
The study was approved by the ethics committee of the
International Agency for Research on Cancer (IARC)
and the ethical committees at the participating centers.
Details of study design and follow-up have been pub-
lished previously [18]. Briefly, follow-up is conducted via
linkages with cancer and population registries with the
exception of centers in Germany, Greece, and Naples,
Italy; these centers utilize a combination of active
follow-up, next-of-kin, and population registries.
Study population
Selection of the cases and controls for this nested case-
control study has been described in detail previously [5].
Briefly, incident ovarian (n = 752), fallopian tube (n = 33),
and primary peritoneal (n = 25) cancers were matched to
up to four controls (n = 1938) on study recruitment center,
age at blood donation (±6 months), time of the day of
blood collection (±1 h), fasting status (<3 h, 3–6 h, >6 h),
menopausal status at blood collection (premenopausal,
perimenopausal, postmenopausal), and current use of
exogenous hormones (OC, menopausal hormone ther-
apy (HT)) at the time of blood draw, as well as men-
strual cycle phase for premenopausal women (3–5
categories, depending on available data) using inci-
dence density sampling.
The primary cross-sectional analyses included pre-
and postmenopausal controls from the nested case-
control study (n = 1910). Given established differences in
circulating CA125 by menopausal status [8], cross-
sectional analyses were restricted to women pre- or
postmenopausal at time of blood collection. Women
were considered premenopausal if they met one of the
following criteria at blood collection: menstruated at
least once in the prior year while not on hormones; were
on hormones but were less than 50 years old; had a hys-
terectomy before last period and were less than 50 years
old; or, age at last menstruation was missing and age
was less than 50. Postmenopausal status was assigned to
women who met one of the following criteria at blood
collection: were not on hormones and had not menstru-
ated in the past year, on hormones and age was 50 or
greater, had a hysterectomy and age was 50 or greater,
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age at last menstruation was missing and age was 50 or
greater. Controls that were perimenopausal or had un-
known menopausal status (n = 28) were excluded. In a
secondary analysis, we evaluated cross-sectional associa-
tions among cases (n = 791). Cases who were perimeno-
pausal or had unknown menopausal status (n = 19) were
excluded from these analyses.
Exposure data
Data on lifestyle and reproductive exposures, as well as
anthropometric measures, were collected at baseline and
included: age at menarche, age at blood draw, OC use
and duration, HT use and duration, type of postmeno-
pausal HT, parity, estimated number of ovulatory cycles
(defined as the time between age at menopause and age
at menarche not taking OCs or pregnant), phase of men-
strual cycle at blood collection (premenopausal women),
tubal ligation, hysterectomy, oophorectomy, BMI, smok-
ing, and family history of breast cancer. Those missing
exposure of interest were excluded from analyses for that
exposure. Among controls, the following variables had
missing observations: age at menarche (n = 78), OC use
(n = 57), duration of OC use (n = 66), parity (n = 136),
number of children (n=43), tubal ligation (n = 1661), IUD
use at recruitment (n = 522), hysterectomy (n = 347), ovu-
latory cycles (n = 385), age at menopause (n = 244), HT
duration (n = 166), HT at blood (n = 359), BMI (n = 94),
smoking (n = 28), pack-years among smokers (n = 10), and
family history of breast cancer (n = 1250).
Laboratory methods
All assays were performed in the Brigham and Women’s
Hospital Obstetrics and Gynecology Laboratory of Geni-
tal Tract Biology using a volume-efficient highly sensi-
tive multiplex platform (Meso Scale Discovery (MSD),
Gaithersburg, MD, USA) based on electrochemilumines-
cence (ECL) detection. Single ECL assays for antigen de-
tection of human CA125 (catalog number K151WC) and
Human Prototype CA15.3 (Catalog number N45ZA-1) and
all reagents related to these two assays were provided by
MSD. The linearity range for CA125 was 0.6–10,000 U/ml,
and for CA15.3 was 0.19–12,500 mU/ml. HE4 and CA72.4
were analyzed using a custom-designed duplex assay. The
following reagents were provided by Fujirebio Diagnostics,
Inc. (Malvern, PA): HE4 protein (IgHE4 antigen), which we
used to generate a calibration curve with a linear range of
0.0137–3600 pM; anti-HE4 capture IgG1 (2H5 mouse
hybridoma); anti-HE4 detection IgG1 (mouse hybridoma
3D8); TAG72 Defined Antigen, which we used to generate
a calibrator curve with a linear range of 0.146–2400 U/ml;
anti-CA72.4 capture IgG1 (mouse hybridoma CC49,
Fujirebio catalog number 110–005); anti-CA72.4 detection
IgG1 (mouse hybridoma B72.3). The samples were split
into batches such that matched case-control sets and
samples from the same study center were kept together in
the same batches. The samples were tested undiluted in the
CA125 singleplex and the HE4/CA72.4 duplex, and they
were tested at a 50-fold dilution in the CA15.3 assay.
Blinded quality control (QC) samples were included on
each assay plate. In blinded QCs with values within the
linearity range of each assay we observed the follow-
ing interplate CVs and min-max (mean) intraplate
CVs: 19% and 3–20 (9)% for CA125, 22% and 3–5% (4%)
for CA15.3, 9% and 4–10% (6)% for HE4, 16% and 1–16%
(6%) for CA72.4). CA72.4 concentrations were below
the lower limit of detection in the blinded QC samples,
therefore CVs are based on the remaining 13 aliquots
(concentration range: 1.15 to 1.87 U/mL).
Statistical analyses
Biomarker concentrations were log-transformed to ob-
tain a more normal data distribution. We assessed each
biomarker for outliers using the generalized extreme stu-
dentized deviate many-outlier procedure [19]. Eight out-
liers were identified for HE4; the influence of these
values was assessed in sensitivity analyses. No outliers
were identified for CA125 or CA15.3. We used general-
ized linear models to estimate the mean CA125, CA15.3,
and HE4 values across categories of each characteristic
and exponentiated results to obtain geometric mean
values in the original scale. Since the majority of the
CA72.4 values (82%) were below the lower detection
limit (1.119 U/mL), we used a logistic regression analysis
with a dichotomous CA72.4 variable (≥1.119 vs. < 1.119
U/mL) as the outcome and results are presented only in
a supplemental table. Wald tests of continuous variables
were used to assess trend. All analyses were adjusted for
matching factors from the parent nested case–control
study: study center (grouped by country), age at blood
draw, fasting status, date of blood draw, menstrual cycle
phase for women premenopausal at blood collection,
OC/HT use at blood collection, and length of follow up.
We adjusted for oophorectomy, number of ovulatory cy-
cles, and smoking status in sensitivity analyses among
premenopausal women, and these factors plus age at
menopause, hysterectomy, and type of HT among post-
menopausal women. Missing indicators were used to ac-
count for missing data for covariates. CA125 and CA15.3
have been reported to vary across the menstrual cycle [20,
21]. Therefore, we evaluated these markers both adjusting
for menstrual cycle phase and standardized using phase-
specific residuals. Results were similar with both ap-
proaches; we present the models adjusted for menstrual
cycle phase.
To assess whether the adjustment for correlates of
these early detection markers improved discrimination
between controls and individuals who subsequently be-
came cases, we evaluated the area under the receiver
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operating characteristic curve (AUC) and compared
AUCs from models including the marker alone to those
including the marker standardized for its correlates.
These analyses were limited to cases who were postmen-
opausal at time of blood collection (n = 590; and their
matched controls), given significant predictors of the
markers were only identified among women postmeno-
pausal at blood collection. AUCs were calculated using
conditional logistic regression models to account for the
matched study design. We calculated absolute risk esti-
mates for ovarian cancer using a model derived in the
EPIC cohort [22] and calibrated the conditional logistic
regression model towards the absolute risk estimates as
an offset variable. We used regression residuals to
standardize the marker concentrations based on signifi-
cant correlates of the marker. Briefly, we calculated the
deviation (residual) from the mean predicted concentra-
tion given each study participant’s profile of correlates.
Correlates included for each marker were: CA125: par-
ity, hysterectomy, unilateral oophorectomy, age at meno-
pause, estrogen-alone HT use, ovulatory cycles, current
smoking; CA15.3: BMI, former smoking; HE4: age at
blood draw, OC use, parity, age at menopause, current
smoking; CA72.4: no correlates identified.
Analyses were conducted using SAS version 9.4
(Cary, NC) and R 3.3.0. All statistical tests were two-
tailed and significant at p < 0.05.
Results
Study participants in the primary cross-sectional ana-
lyses restricted to controls were mean age 56 years at
blood collection, and 74% were postmenopausal (n =
1421; premenopausal, n = 489). The majority of partici-
pants were parous (89%), half were ever users of OCs at
the time of blood collection, and 33% of postmenopausal
women reported using HT use at the time of blood col-
lection. Average BMI was 25.8 kg/m2, and 19% reported
smoking at the time of blood draw (Table 1). Character-
istics of the full nested case-control study population
have been presented previously [5]. Briefly, cases were
median age 63 years at diagnosis (range: 31–86 years),
with median 6 years between blood collection and diag-
nosis (range: 0–16 years). The majority of cases were di-
agnosed with tumors of serous histology (n = 443; 55%).
CA125 concentrations differed significantly by meno-
pausal status at blood collection, with lower concentrations
observed among postmenopausal women (premenopausal:
26.1 U/mL; postmenopausal: 18.4 U/mL; p < 0.01; Table 2).
Concentrations of CA15.3 were significantly higher among
postmenopausal (617.5 U/mL) compared to premenopausal
(552.9 U/mL, p = 0.02) women. HE4 concentrations did not
differ by menopausal status at blood collection (p = 0.92).
Among premenopausal women, biomarker concentrations
did not differ significantly by menstrual cycle phase (Fig. 1).
Significant associations between epidemiologic factors
and the investigated markers were predominantly ob-
served among women who were postmenopausal at
blood collection. Specifically, parity (p = 0.04), higher
number of full-term pregnancies among parous women
(ptrend = 0.02), older age at menopause (ptrend < 0.01), and
greater estimated lifetime number of ovulatory cycles
(ptrend < 0.01) were all associated with higher CA125
concentrations, whereas hysterectomy, unilateral oophor-
ectomy, estrogen-only hormone therapy (vs. never use),
and current smoking (vs. never smoking) were associated
with lower concentrations (all associations p < 0.01). For
CA125, no associations were observed among premeno-
pausal women, with the exception of an inverse associ-
ation between OC at blood collection and CA125 (users:
19 U/mL; non-users: 30 U/mL; p < 0.01). For CA15.3,
higher BMI (ptrend < 0.01) and former smoking versus
never smoking (p = 0.03) were associated with higher con-
centrations among postmenopausal women, while youn-
ger age at blood collection (p = 0.03) was associated with
higher CA15.3 among premenopausal women. None of
the remaining exposures were associated with circulating
CA15.3. Older age at blood collection was associated with
higher HE4 concentrations in postmenopausal women
(ptrend < 0.01), whereas longer duration of OC use (ptrend <
0.01), higher parity (ptrend = 0.02), and older age at meno-
pause were associated with lower concentrations. Current
smoking, relative to never smoking, was associated with
higher HE4 concentrations in both pre- and postmeno-
pausal women (p < 0.01).
CA72.4 was evaluated as a dichotomous outcome (i.e.,
detectable vs. non-detectable concentrations), given than
82% of values were below the detection limit. We ob-
served no associations between any of the examined epi-
demiologic risk factors and detectable vs. non-detectable
CA72.4 concentrations, except suggestively higher
CA72.4 with a higher BMI (≥25 vs. < 25, p = 0.05;
Additional file 1: Table S1).
Tubal ligation (yes/no), age at menarche (<12, 12, 13,
14, 14+ years), IUD use (yes/no), and family history of
breast cancer (yes/no) were not associated with any of
the examined markers. The associations between oo-
phorectomy, hysterectomy, ovulatory cycles with CA125,
as well as the association between age at blood draw and
CA15.3 in premenopausal women, were attenuated and
no longer statistically significant after adjustment for the
other investigated factors (i.e., adjusted for matching fac-
tors plus all significant correlates of the markers presented
in the tables; Table 3 and Additional file 1: Table S2). The
remaining associations were similar after adjustment. Fi-
nally, results were essentially unchanged in sensitivity ana-
lyses excluding eight outlying HE4 values.
We observed few significant associations between the
evaluated lifestyle and reproductive factors and the
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examined markers among ovarian cancer cases in the
nested case-control study (Additional file 1: Table S3).
There were no significant associations with CA125
among cases. However, among premenopausal women
diagnosed with high-grade serous ovarian cancer over
follow-up, current smoking was associated with lower
CA125 (data not shown). Longer duration of OC use
was associated with lower CA15.3 levels in postmeno-
pausal women. Interestingly, higher parity and fewer
ovulatory cycles were associated with lower premeno-
pausal CA15.3 levels while the same exposures were as-
sociated with higher premenopausal HE4 levels. Among
women diagnosed with high-grade serous disease, the
association between OC use and HE4 levels persisted
but the other associations did not (data not shown).
Finally, we investigated the discrimination of these
markers before and after adjusting the markers (using bio-
marker residuals) for the epidemiologic factors identified
as significant correlates in the cross-sectional analyses.
These analyses were conducted in strata of time between
blood collection and diagnosis (<1 year, 1 to <2 years, 2 to
<3 years, ≥3 years). AUCs for the markers (individually
and combined) were essentially unchanged when the
marker values were adjusted for the epidemiologic corre-
lates (e.g., AUC<1 year, postmenopausal women, markers
unadjusted: 0.87 (95% confidence interval (CI): 0.81–0.93);
marker residuals: 0.89 (95% CI: 0.84–0.95); Table 4).
Discussion
We present results from a large, cross-sectional study
evaluating lifestyle and reproductive factors and ovarian
cancer early detection markers. Adjustment for the iden-
tified correlates of these markers in early detection pre-
diction models did not improve discrimination.
We confirmed previously reported observations [8,
13–16] of lower CA125 levels in post- vs. premeno-
pausal women. CA15.3 levels were significantly higher
among postmenopausal women. HE4 concentrations did
not vary by menopausal status. We examined the effect
of age at blood collection within strata of menopausal
status and did not observe significant associations for
CA125 and CA15.3, with the exception of a significant
inverse association between age and CA15.3 among
women who were premenopausal at blood collection.
Large prior studies have reported a modest inverse associ-
ation between age and CA125 [7, 8], evident in both pre-
[8] and postmenopausal women [7, 8], whereas prior stud-
ies on CA15.3 observed a modest positive [16, 17] or no
[23] association. However, neither of the studies observing
a positive association between age and CA15.3 accounted
for menopausal status at blood collection. We observed
higher HE4 levels with older age only among women post-
menopausal at blood collection. A positive association be-
tween age and HE4 has been previously reported
(reviewed in [10, 24]). Older age at menopause was posi-
tively associated with CA125 concentrations, as has been
observed previously [6–8], and inversely associated with
HE4. We observed no association between age at meno-
pause and CA15.3.
Among postmenopausal women, there was a modest
inverse association between longer duration of OC use
and HE4 concentrations. OC use has not previously
been associated with circulating HE4 [11, 25]. However,
data on OC duration are sparse. HE4 is expressed
through the female reproductive tract [26], with the ex-
ception of the ovary. OC use inhibits cyclic proliferation
leading to endometrial atrophy and predecidual changes
in the stroma [27], though this is somewhat dependent
on formulation. Therefore, OC use may impact HE4
concentrations via the effect on the endometrium. OC
use may also impact mucin expression through upregu-
lation of proinflammatory pathways recently shown to
affect immunity in the distal reproductive tract [28]. Cir-
culating concentrations of CA125 did not differ by dur-
ation of past OC use in our study, consistent with prior
investigations [7, 23]. Use of estrogen-alone HT was as-
sociated with lower CA125 concentrations; these
Table 1 Population characteristics for controls included in cross
sectional analysis of CA125, CA15.3, HE4, and CA72.4: EPIC ovarian
cancer nested case-control study
Characteristic Total sample
n = 1910
Age at blood draw, mean (sd) 56.3 (8.3)
Age at menarche, mean (sd) 13.3 (1.6)
Ever OC use, n (%) 930 (50%)
OC duration among users, years, mean (sd) 8.5 (8.1)
Parous, n (%) 1573 (89%)
Number of children among parous, mean (sd) 2.4 (1.1)
Unilateral oophorectomy, n(%) 70 (4%)
Postmenopausal, n (%) 1421 (74%)
HT use among postmenopausal women 463 (33%)
BMI, kg/m2, mean (sd) 25.8 (4.5)
Current smoker, n (%) 360 (19%)
Packyears of smoking among current smokers,
mean (sd)
21.4 (13.5)
CA125 (U/mL), geometric mean (95% CI) 20.1 (19.6, 20.7)
CA15.3 (mU/mL), geometric mean (95% CI) 600.4 (585.7, 615.5)
HE4 (pM), geometric mean (95% CI)a 18.9 (18.2, 19.5)
CA72.4 (U/mL), geometric mean (95% CI)a 0.69 (0.66, 0.72)
Some participants had missing data: age at menarche (n = 78), oral contraceptive
use (n = 57), duration of OC use (n = 66), parity (n = 136), number of children
(n = 43), BMI (n = 94), smoking (n = 28), packyears among current smokers
(n = 10), CA125 (n = 10), CA15.3 (n = 17), HE4 (n = 1197), CA72.4 (n = 1197)
a Restricted to 713 controls with HE4/CA72.4 measurements. Note, participants
with CA72.4 less than the limit of detection were assigned value of 0.56
(half of the limit of detection); geometric mean (95% CI) retricted to women with
values above the limit of detection: 2.4 (2.0-2.9)
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associations persisted in multivariable models but were
only evident among women with hysterectomy in strati-
fied models. Administered transdermal 17ß-estradiol has
previously been associated with an increase in circulat-
ing CA125 in women without hysterectomy [29] and
HT use (overall; formulation not specified) was associ-
ated with higher CA125 in the Prostate, Lung, Colorec-
tal and Ovarian Cancer Screening Trial (PLCO) [6].
However, a positive association between HT and CA125
has not been universally observed [23, 30]. Cengiz et al.
observed lower CA15.3 among women using estrogen-
alone HT [31] in an analysis limited to women with hys-
terectomy and bilateral salpingo-oophorectomy. Thus,
comparability to our study population is limited. One
additional investigation observed no association between
HT use (overall) and circulating CA15.3 [23]. HT use
was not associated with HE4, consistent with others
[12], or CA72.4 in the current investigation.
Parity was associated with higher CA125 concentrations
and lower HE4 concentrations among women who were
postmenopausal at blood collection. The endometrium is a
major source of CA125 in healthy women, and it is plaus-
ible that the extensive pregnancy-induced changes in the
endometrium contribute to long-term changes in cir-
culating CA125 and HE4. Further, data suggest CA125
increases during early pregnancy and close to delivery
[32–36]; it is plausible that the higher concentrations
observed in pregnancy persist post-pregnancy. One
study reported higher CA125 concentrations among
women reporting parity of two or higher [37], how-
ever, an association between parity and CA125 has
not consistently been observed among healthy women
[7]. Prior data suggest lower CA125 concentrations in
uterine flushing from women with recurrent miscar-
riages [38]. In turn, recurrent miscarriage is associated
with lower parity. Additional studies are needed to clarify
the impact of parity on subsequent circulating CA125
concentrations. The inverse association between parity
and HE4 concentrations is consistent with one prior
investigation [39]. However, other investigations have
observed no association between parity and HE4 [11, 12].
We observed no association between parity and CA72.4
Fig. 1 Variation of markers across the menstrual cycle. Box plots and geometric means (red line) and 95% confidence intervals (red cloud) for CA125
(panel a), CA15.3 (panel b), HE4 (panel c), and CA72.4 (panel d; among women with concentrations > LOD)
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or CA15.3; for CA15.3, this is consistent with an earlier
study [23].
Higher BMI was associated with higher CA15.3 con-
centrations among postmenopausal women in our study.
This is consistent with a prior study [17] in men and
women, suggesting that the effect is not explained solely
by higher estrogen levels in obese postmenopausal
women. An additional small study (n < 50) reported no
significant association between BMI and circulating
CA15.3 [40]. However, the analysis was limited to
Table 3 Multivariate adjusted associations between epidemiologic characteristics and CA125, CA15.3, and HE4 among controls
postmenopausal at blood collection: EPICa
CA125 CA15.3 HE4b
beta p beta p beta p
Age at blood draw (continuous) 0.016 <0.0001
Duration of oral contraceptive use (continuous) −0.007 0.009
Parity (continuous)c 0.030 0.03 −0.036 0.03
Hysterectomy −0.053 0.34
Uniliateral oophorectomy −0.104 0.18
Age at menopause (continuous) 0.019 0.0009 −0.015 0.03
Type of HT (E alone vs. never) −0.120 0.17
Ovulatory cyclesc, d(continuous) −0.0001 0.76
BMI (kg/m2; continuous) 0.013 0.003
Smoking
Former vs never 0.006 0.87 0.081 0.03 −0.003 0.95
Current vs never −0.164 <0.0001 −0.018 0.66 0.385 <0.0001
a1 control missing CA125 and 8 missing CA153; b Restricted to 538 controls; cmodel was run once including parity and excluding ovulatory cycles, then run again
excluding parity and including ovulatory cycles. With the exception of ovulatory cycles, the betas and p-values shown are for the model including parity; d time
between menarche and menopause with time subtracted for oral contraceptive use, pregnancy and breastfeeding. Note: Italicized p values indicate statistically
significant associations
Table 4 Discriminatory ability of ovarian cancer biomarkers adjusted for predictors of those biomarkers among women
postmenopausal at blood collection: EPIC
Time Between Blood Collection and Diagnosis
<1 year 1–2 years 2–3 years >3 years
CA125
biomarker 0.86 (0.79–0.92) 0.78 (0.71–0.84) 0.61 (0.51–0.70) 0.57 (0.54–0.61)
adjusted biomarkera 0.85 (0.79–0.92) 0.78 (0.72–0.85) 0.60 (0.51–0.70) 0.57 (0.54–0.61)
CA15.3
biomarker 0.66 (0.57–0.75) 0.60 (0.52–0.68) 0.61 (0.52–0.70) 0.56 (0.52–0.59)
adjusted biomarkera 0.67 (0.57–0.76) 0.60 (0.52–0.68) 0.61 (0.52–0.70) 0.56 (0.52–0.59)
HE4
biomarker 0.84 (0.77–0.90) 0.68 (0.61–0.76) 0.61 (0.52–0.70) b
adjusted biomarkera 0.84 (0.77–0.90) 0.70 (0.62–0.77) 0.62 (0.52–0.71) b
CA72.4
biomarker 0.76 (0.69–0.84) 0.67 (0.59–0.75) 0.61 (0.51–0.70) b
adjusted biomarkera c c c b
All biomarkers CA125 and CA15.3b
biomarker 0.87 (0.81–0.93) 0.79 (0.73–0.85) 0.60 (0.51–0.70) 0.57 (0.54–0.61)
adjusted biomarkera 0.89 (0.84–0.95) 0.80 (0.73–0.86) 0.62 (0.53–0.71) 0.57 (0.54–0.61)
aBiomarker residuals accounting for significant predictors: CA125: parity, hysterectomy, unilateral oophorectomy, age at menopause, E only HT, ovulatory cycles,
current smoking; CA15.3: BMI, former smoking; HE4: age at blood draw, OC use, parity, age at menopause, current smoking; CA72.4: none; bHE4 and CA72.4 only
measured in cases diagnosed within 3 years of blood collection; cNo predictors identified
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comparisons between obese vs. non-obese (BMI ≥30 vs.
<30). We observed no association between BMI and
CA125, HE4, or CA72.4. In the Prostate, Lung, Colorectal
and Ovarian Cancer Screening Trial (PLCO), obese women
had 3% lower CA125, relative to normal weight
women (p < 0.001) [6]. Only 15% of the participants in the
current investigation were obese (n = 271), as compared to
almost 24% of PLCO study participants (n = 6063), and
the current study was not statistically powered to detect
such a small relative difference. Previous investigations on
BMI and HE4 are mixed, reporting no [9, 10, 39], inverse
[41], and positive [12] associations.
Current smoking was inversely associated with CA125
concentrations. This is consistent with three prior inves-
tigations in recent large, well-characterized populations
[6–8], though significant associations were not observed
in smaller prior studies [39, 42, 43]. Smoking may re-
duce CA125 concentrations via its effect on endogenous
estrogens. Smoking is inversely associated with endogen-
ous estrogens [44], whereas administered estradiol is as-
sociated with higher circulating CA125 [29]. Further,
smoking is associated with earlier age at menopause
[45], which, in turn, is associated with lower CA125. Fi-
nally, CA125 is expressed in the respiratory tract [46],
and smoking may reduce circulating CA125 concentra-
tions via damage to the respiratory tract epithelia or via
more general immunosuppressive effects. We observed a
higher concentrations of HE4 among women reporting
current smoking, compared to never smokers, consistent
with others (reviewed in [10]). As with CA125, HE4 is
expressed in the oral cavity and respiratory tract, and it
has been hypothesized that higher HE4 in smokers
may be due to smoking-induced inflammation [41].
However, the mechanisms underlying the associations
between CA125 and HE4 and smoking remain to be
fully characterized. Former smoking, but not current
smoking, was associated with higher CA15.3 concen-
trations in this investigation. One prior investigation
observed no association between smoking and CA15.3
concentrations [17].
As expected, and consistent with prior studies [7, 47],
we observed lower CA125 concentrations among
women reporting hysterectomy, though this association
did not persist in the fully adjusted model. A similar pat-
tern was observed for oophorectomy. While ovarian cells
do not express CA125, this marker is expressed in the
fallopian tube epithelium. Prior studies have not ob-
served an association between oophorectomy and
CA125 [6, 7, 48] or have concluded that the decline in
CA125 after bilateral salpingectomy-oophorectomy is
not due to ovarian CA125 [47]. In our investigation, uni-
lateral oophorectomy was associated with CA125 only
before adjustment for hysterectomy and HT use, sup-
porting prior observations that oophorectomy is not
independently associated with CA125 concentrations.
CA15.3, HE4, and CA72.4 were similar in women
with and without reported hysterectomy or bilateral
oophorectomy.
Significant associations observed in this study were
predominantly observed among women who were post-
menopausal at blood collection. CA125 and CA15.3
have been reported to vary across the menstrual cycle
[20, 21]; substantial variation was not observed among
premenopausal women in this investigation. However,
we (i) adjusted for menstrual cycle phase and (ii) used
phase-specific residuals to evaluate potential variability.
Results were similar with both approaches. We were un-
able to assess cross-sectional associations during individ-
ual phases of the menstrual cycle. Our cross-sectional
analysis between epidemiologic factors and early detec-
tion markers yielded few significant associations in
women who subsequently developed ovarian cancer.
Among high grade serous cases, significant findings were
limited to only current smoking and lower CA125 in
premenopausal women and oral contraceptives use with
lower CA15.3 in postmenopausal women but may be
due to chance given these associations were not ob-
served in controls.
We hypothesized that inclusion of significant corre-
lates of the evaluated early detection markers would im-
prove discrimination of the early detection prediction
models including these markers as this would, in part,
account for sources of variation in these markers due to
factors other than ovarian malignancy. However, we ob-
served no improvement of the AUC in models adjusting
for the epidemiologic correlates identified in the cross-
sectional analyses and results from this study do not
support the approach of adjusting CA125, CA15.3, HE4
or CA72.4 concentrations for their correlates to improve
ovarian early detection models. An alternative approach
would be to develop personalized cutpoints for the
markers, based on a woman’s individual characteristics,
as has been proposed for CA125 by menopausal status
[8]. The current study was not designed to define or as-
sess the utility of individualized cutpoints for ovarian
cancer early detection; however, this should be explored
in future studies designed for this purpose.
Conclusions
This investigation adds to the limited data on correlates
of CA125, CA15.3, HE4, and CA72.4 in healthy women,
and provides the first data by menopausal status at blood
collection. While we did not observe improvements in
discrimination of early detection prediction models after
accounting for these correlates, this data may inform
future research on the development of individualized
early detection marker cutpoints based on epidemiologic
factors.
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